Portal de investigación
- Inicio
- Proyectos y Estudios
- Estudio fase 3, multicéntrico, doble ciego, controlado con principio activo para evaluar la eficacia, seguridad, tolerabilidad, farmacocinética y farmacodinamia de ozanimod oral en comparación con fingolimod oral en niños y adolescentes con esclerosis múltiple remitente-recurrente.
Estudio fase 3, multicéntrico, doble ciego, controlado con principio activo para evaluar la eficacia, seguridad, tolerabilidad, farmacocinética y farmacodinamia de ozanimod oral en comparación con fingolimod oral en niños y adolescentes con esclerosis múltiple remitente-recurrente.
Datos básicos
- Protocolo:
- IM047-050
- EUDRACT:
- NCT:
- Centro:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Año de incio:
- 2025
- Año de finalización:
Documentos
- No hay documentos
Grupos
Financiadores - Promotores
Resultados del Ensayo Clínico
[Translated article] Knowledge of biological therapy in patients with immune-mediated diseases. BIOINFO study.
Segui-Solanes, Carlos; (...); Borras-Blasco, Joaquin
Article. 10.1016/j.farma.2024.08.002. 2024
[Translated article] New challenges in advanced therapies.
Megías-Vericat JE; (...); Poveda Andrés JL
Article. 10.1016/j.farma.2024.05.001. 2024
[Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice.
Chovi-Trull, Maria; (...); Andres, Jose Luis Poveda
Article. 10.1016/j.farma.2024.12.007. 2025
Associations between antidiabetic medications and cerebrospinal fluid biomarkers of Alzheimer's disease.
Garcia-Lluch, Gemma; (...); Chafer-Pericas, Consuelo
Article. 10.1177/13872877241304995. 2024
Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: DISCOVER study
Oreja-Guevara, Celia; (...); Rio, Jordi
Article. 10.1016/j.msard.2024.105787. 2024
Clinical trajectories of patients with multiple sclerosis from onset and their relationship with serum neurofilament light chain levels
Quintanilla-Bordas, Carlos; (...); Casanova, Bonaventura
Article. 10.3389/fneur.2024.1477335. 2024
Comparative Assessment of Simoa and Lumipulse for Measuring Serum Neurofilament Light Chain in Multiple Sclerosis Patients
Gasque-Rubio, Raquel; (...); Perez-Miralles, Francisco
Article. 10.1155/2024/1950913. 2024
Cost-effectiveness and cost-utility analysis of haemate-P versus other von willebrand disease treatments in Spain.
Megias-Vericat, Juan E; (...); Yan, Songkai
Article. 10.1080/13696998.2025.2474886. 2025
Development and testing of a mobile app for systematic collection of patient-reported outcomes (PROs) in patients with hemophilia.
Megias-Vericat, J E; (...); Poveda Andres, J L
Letter. 10.1016/j.thromres.2024.109122. 2024
Elevation of serum neurofilament light-chain levels disclose possible occult progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient receiving ozanimod: a case report.
Quintanilla-Bordás C; (...); Pérez-Miralles FC
Case Reports. 10.3389/fimmu.2024.1465678. 2024
Evaluating the complement C1q levels in serum and cerebrospinal fluid in multiple sclerosis patients: Could it serve as a valuable marker in clinical practice?
Tortosa-Carreres J; (...); Pérez-Miralles FC
Article. 10.1016/j.jneuroim.2024.578428. 2024
Improvements in quality of life of patients with multiple sclerosis receiving alemtuzumab in clinical practice: the LEMVIDA study.
Meca-Lallana, Jose Eustasio; (...); Toledo, Baldo
Article. 10.1186/s41687-024-00822-9. 2024
Increased EBNA1-specific antibody response in primary-progressive multiple sclerosis
Comabella, Manuel; (...); Luenemann, Jan D.
Article. 10.1007/s00415-024-12763-w. 2025
Influence of Statin Potency and Liposolubility on Alzheimer's disease patients: a population-based study.
Garcia-Zamora, Mar; (...); Chafer-Pericas, Consuelo
Article. 10.1016/j.phrs.2024.107446. 2024
Insights from a 7-Year Dementia Cohort (VALCODIS): ApoE Genotype Evaluation.
Baquero, Miguel; (...); Chafer-Pericas, Consuelo
Article. 10.3390/jcm13164735. 2024
Mental, emotional and social dimensions of quality of life and their relationship with physical and functional status in adults with haemophilia.
Rodríguez MA; (...); Chimeno-Hernández A
Article. 10.1016/j.thromres.2024.109181. 2024
New challenges of advanced therapies.
Megías-Vericat JE; (...); Poveda Andrés JL
Article. 10.1016/j.farma.2023.11.008. 2024
Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review.
Ballesta-Lopez, Octavio; (...); Poveda-Andres, Jose Luis
Article. 10.3390/ijms26041760. 2025
Renal function's impact on serum neurofilament levels in patients with multiple sclerosis: an exploratory analysis.
Tortosa-Carreres, Jordi; (...); Perez-Miralles, Francisco
Article. 10.1007/s10072-024-07772-6. 2024
Response to letter to the editor: An in-depth look at the relationship between anti-diabetic drugs and Alzheimer's disease.
Garcia-Zamora, Mar; (...); Pardo Albiach, Juan
Letter. 10.1016/j.phrs.2024.107396. 2024
Response to letter to the editor: Expanding perspectives on the relationship between statin potency and lipophilicity in Alzheimer's disease management.
Garcia-Zamora, Mar; (...); Pardo, Juan
Letter. 10.1016/j.phrs.2025.107595. 2025
Selecting a Brief Cognitive Screening Test Based on Patient Profile: It Is Never Too Early to Start
Garcia-Lluch, Gemma; (...); Moreno, Lucrecia
Article. 10.3390/jcm13196009. 2024
Serum biomarkers at disease onset for personalized therapy in multiple sclerosis.
Monreal E; (...); Villar LM
Article. 10.1093/brain/awae260. 2024
Serum neurofilament light chain and glial fibrillary acidic protein levels at disease onset unveil immunological pathways of disability acquisition in multiple sclerosis
Monreal, Enric; (...); Villar Guimerans, Luisa Maria
Meeting Abstract. 2024
Toxic-metabolic encephalopathy induced by metronidazole and disulfiram: classics never die.
Chovi-Trull, Maria; (...); Poveda-Andres, Jose Luis
Article. 10.1136/ejhpharm-2024-004184. 2024